The global market for seasonal influenza vaccines is expected to experience significant growth, with a projected value of $24.1 billion by 2035, up from $10.2 billion in 2025, at a compound annual growth rate (CAGR) of 9%. Major multinational vaccine manufacturers, such as GlaxoSmithKline, Sanofi, Seqirus, and AstraZeneca, produce trivalent flu vaccines under various brand names, including Fluarix, Flulaval, Fluzone, Fluad, and FluMist. These vaccines are commonly administered in the US and other Western countries to protect against seasonal influenza, a contagious respiratory illness caused by influenza viruses that spread through airborne respiratory droplets or direct contact.
Seasonal influenza viruses evolve rapidly, requiring annual updates to vaccine compositions. Global surveillance systems, such as the World Health Organization’s (WHO) Global Influenza Surveillance and Response System (GISRS), guide these updates. Recently, Zydus introduced a new vaccine, which is significant for India, as it aligns with global recommendations. Since March 2020, the influenza B Yamagata virus has not circulated in countries like India, leading global regulatory bodies, including the WHO and Centers for Disease Control and Prevention (CDC), to recommend its exclusion from vaccine formulations.
The introduction of new vaccines, such as the one from Zydus, is expected to contribute to the growth of the seasonal influenza vaccines market. The market’s expansion will also be driven by increasing awareness about the importance of vaccination, particularly in regions with limited access to healthcare services. As the global population becomes more aware of the risks associated with seasonal influenza, the demand for effective vaccines is likely to rise, driving the market’s growth. With the global pattern of influenza virus circulation continuously evolving, the development of new vaccines and updates to existing ones will remain crucial in protecting against this contagious respiratory illness.